Possible inhibitory mechanism of FK506 (tacrolimus hydrate) ointment for atopic dermatitis based on animal models

European Journal of Pharmacology

Volumn 379, Issue 2-3, 1999, Pages 183-189

  Sengoku, Takanori ^a   Morita, Kyoko ^a   Sakuma, Shozo ^a   Motoyama, Yukio ^a   Goto, Toshio ^a  

^a Med Chemistry Research Laboratories   (Japan)

Author keywords

Animal model; Atopic dermatitis; Delayed allergic reaction; FK506 ointment; Inhibitory mechanism

Indexed keywords

ALCLOMETASONE DIPROPIONATE; OINTMENT BASE; TACROLIMUS; TUBERCULIN;

ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MALE; MOUSE; NONHUMAN; OINTMENT; PASSIVE SKIN ANAPHYLAXIS; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION; TOPICAL DRUG ADMINISTRATION;

ANIMALS; DERMATITIS, ATOPIC; DRUG EVALUATION, PRECLINICAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; RATS; RATS, INBRED BN; RATS, INBRED LEW; TACROLIMUS; TUBERCULIN; VASCULITIS, ALLERGIC CUTANEOUS;

EID: 0032704624     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00500-2     Document Type: Article

References (33)

1. Andersson J., Nagy S., Groth C.G., Andersson U. Effects of FK 506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. Immunology. 75:1992;136-142.
2. Aoyama H., Tabata N., Tanaka M., Uesugi Y., Tagami H. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br. J. Dermatol. 133:1995;494-496.
3. Denis M., Forget A., Pelletier M., Turcotte R., Skamene E. Control of the Bcg gene of early resistance in mice to infections with BCG substrains and atypical mycobacteria. Clin. Exp. Immunol. 63:1986;517-525.
4. Fujii Y., Gogi H., Takakura K., Sakuma S., Goto T. Effect of tacrolimus ointment on a pharmacological model of skin inflammation by repeated topical application of antigen in rats. Clinical Report (Kiso to rinsho). 31:1997;2693-2700.
5. Grewe M., Gyufko K., Schöpf E., Krutmann J. Lesional expression of interferon-γ in atopic eczema. Lancet. 343:1994;25-26.
6. Grewe M., Walther S., Gyufko K., Czech W., Schöpf E., Krutmann J. Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J. Invest. Dermatol. 105:1995;407-410.
7. + resting memory T-cell pool is influenced by major histocompatibility complex. Transplantation Proceedings. 25:1993;2782-2783.
8. Gros P., Skamene E., Forget A. Genetic control of natural resistance to Mycobacterium bovis (BCG) in mice. J. Immunol. 127:1981;2417-2421.
9. Hamid Q., Boguniewicz M., Leung D.Y.M. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J. Clin. Invest. 94:1994;870-876.
10. Hiroi J., Sengoku T., Morita K., Kishi S., Sato S., Ogawa T., Tsudzuki M., Matsuda H., Wada A., Esaki K. Effect of tacrolimus hydrate (FK506) ointment on spontaneous dermatitis in NC/Nga mice. Jpn. J. Pharmacol. 76:1998;175-183.
11. Hodson D., Oliveira D.B.G. The strain difference in the effect of mercuric chloride on antigen-triggered serotonin release from rat mast cells is not mediated via interferon-γ Immunology. 89:1996;463-467.
12. Homey B., Assmann T., Vohr H.W., Ulrich P., Lauerma A.I., Ruzicka T., Lehmann P., Schuppe H.C. Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses. J. Immunol. 160:1998;5331-5340.
13. + T cells. Immunol. Today. 12:1991;392-395.
14. Kiely P.D.W., Thiru S., Oliveira D.B.G. Inflammatory polyarithritis induced by mercuric chloride in the Brown Norway rat. Laboratory Investigation. 73:1995;284-293.
15. Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H., Imanaka H. FK-506, a novel immunosuppressant isolated from a Streptomyces: I. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. 40:1987;1249-1255.
16. Lauerma A.I., Maibach H.I. Topical FK506-clinical potential or laboratory curiosity? Dermatology. 188:1994;173-176.
17. Lauerma A.I., Maibach H.I., Granlund H., Erkko P., Kartamaa M., Stubb S. Inhibition of contact allergy reactions by topical FK506. Lancet. 340:1992;556.
18. Lauerma A.I., Stein B.D., Homey B., Lee C.H., Bloom E., Maibach H.I. Topical FK506: suppression of allergic and irritant contact dermatitis in the guinea pig. Arch. Dermatol. Res. 286:1994;337-340.
19. Martinez-Abrajan D.M. Differential specific humoral response of susceptible and resistant mice infected with Mycobacterium lepraemurium. Rev. Latinoam. Microbiol. 35:1993;171-176.
20. Meingassner J.G. Immunosuppressive macrolides of the type FK506: a novel class of topical agents for treatment of skin diseases? J. Invest. Dermatol. 98:1992;851-855.
21. Mihm M.C. Jr., Soter N.A., Dvorak H.F., Austen K.F. The structure and morphology of normal and atopic eczema. J. Invest. Dermatol. 67:1976;305-312.
22. Nakagawa H., Etoh T., Ishibashi Y., Higaki Y., Kawashima M., Torii H., Harada S. Tacrolimus ointment for atopic dermatitis. Lancet. 344:1994;883.
23. Oliveira D.B.G., Gillespie K., Wolfreys K., Mathieson P.W., Qasim F., Coleman J.W. Compounds that induce autoimmunity in the Brown Norway rat sensitize mast cells for mediator release and interleukin-4 expression. Eur. J. Immunol. 25:1995;2259-2264.
24. Pauwels R., Bazin H., Plateau B., Van der Straeten M. The influence of antigen dose on IgE production in different rat strains. Immunology. 36:1979;151-157.
25. Peszkowski M.J., Warfvinge G., Larsson Å. Allergic and irritant contact responses to DNFB in BN and LEW rat strains with different TH1/TH2 profiles. Acta Derm.-Venereol. 74:1994;371-374.
26. Rao A. NF-Atp: a transcription factor required for the co-ordinate induction of several cytokine genes. Immunol. Today. 15:1994;274-281.
27. Ruzicka T., Bieber T., Schöpf E., Rubins A., Dobozy A., Bos J.D., Jablonska S., Ahmed I., Thestrup P.K., Daniel F., Finzi A., Reitamo S. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N. Engl. J. Med. 337:1997;816-821.
28. Salerno A., Bonanno C.T., Caccamo N., Cigna D., Dominici R., Ferro C. The effect of cyclosporin A, FK-506 and rapamycin on the murine contact sensitivity reaction. Clin. Exp. Immunol. 112:1998;112-119.
29. Schreiber S.L., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Immunol. Today. 13:1992;136-142.
30. Scott P., Eaton A., Gause W.C., di Zhou X., Hondowicz B. Early IL-4 production does not predict susceptibility to Leishmania major. Exp. Parasitol. 84:1996;178-187.
31. Sengoku T., Morita K., Sato S., Sakuma S., Ogawa T., Hiroi J., Fujii T., Goto T. Effects of tacrolimus ointment on type I (immediate and late) and IV (delayed) cutaneous allergic reactions in mice. Folia Pharmacol. Jpn. 112:1998;221-232.
32. Thepen T., Langeveld-Wildschut E.G., Bihari I.C., van Wichen D.F., van Reijsen F.C., Mudde G.C., Bruijnzeel-Koomen C.A.F.M. Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. J. Allergy. Clin. Immunol. 97:1996;828-837.
33. Yamada N., Wakugawa M., Kuwata S., Yoshida T., Nakagawa H. Chronologic analysis of in situ cytokine expression in mite allergen-induced dermatitis in atopic subjects. J. Allergy Clin. Immunol. 96:1995;1069-1075.